Ichinose T

No ORCID on file · 4 papers in corpus · active 2021-2025

Study types

  • article 1
  • case-report 1

Condition tags

  • adenomyosis 2
  • chronic_pelvic_pain 1
case-report 2025
Sequential therapy of dienogest following relugolix for adenomyosis and impact on symptoms and serum CA125 levels: a case series
BMC women's health ·doi:10.1186/s12905-025-03681-8

BACKGROUND: Adenomyosis, characterized by endometrial tissue within the uterine muscle, often presents with severe pelvic pain and menorrhagia. This case series demonstrates the efficacy of sequential therapy involving relugolix followed by…

2024
Prognostic analysis of peritoneal washing cytology during interval debulking surgery in advanced ovarian cancer.
Journal of ovarian research ·doi:10.1186/s13048-024-01494-1

BackgroundInterval debulking surgery (IDS) following neoadjuvant chemotherapy is a treatment option for advanced ovarian cancer. Optimal surgery is required for better survival; however, while peritoneal washing cytology (PWC) has been iden…

2022
Case report: Posterior reversible encephalopathy syndrome, an adverse effect of lenvatinib and pembrolizumab combination therapy, in a patient with advanced endometrial cancer.
Frontiers in oncology ·doi:10.3389/fonc.2022.1079716

BackgroundLenvatinib-pembrolizumab combination (LEAP) is an approved therapy in Japan for advanced endometrial cancer, based on the data from the KEYNOTE-775 clinical trial. We report a case of posterior reversible encephalopathy syndrome (…

article 2021
A case of adenomyosis with leiomyoma that was effectively treated with relugolix and kamishoyosan add-on therapy
BMC women's health ·doi:10.1186/s12905-021-01442-x

Abstract Background Recently, relugolix, an oral gonadotropin-releasing hormone receptor antagonist, has been considered an effective therapy for leiomyoma based on a phase 3 study in Japanese women. Leiomyoma combined with severe adenomyos…